Federated Hermes
LCTX icon

Federated Hermes’s Lineage Cell Therapeutics LCTX Stock Holding History

Federated Hermes’s Portfolio LCTX Stock Details LCTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-20
Closed -$1K – 2307
2019
Q4 		$1K Buy
+20
New +$17 ﹤0.01% 2109

Other funds holding LCTX

BC
Broadwood Capital New York $1.91B AUM 44.39% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DC
Defender Capital Charlotte, North Carolina $308M AUM 4.52% 1-Year Est. Return
PGP
Prescott General Partners Boca Raton, Florida $1.96B AUM 58.65% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return
NFC
Northeast Financial Consultants Westport, Connecticut $2.45B AUM 15.14% 1-Year Est. Return

Federated Hermes's LCTX Position: Q1 2020 in Review

Federated Hermes sold out of Lineage Cell Therapeutics (LCTX) in Q1 2020, closing a stake of 20 shares — an estimated $1K sold.

Federated Hermes first reported a position in LCTX in Q4 2019 and held it in 1 quarter. The position peaked at $1K in Q4 2019. 97 funds tracked by Wall St. Rank hold LCTX as of Q1 2020.

  • Federated Hermes reported no remaining Lineage Cell Therapeutics position as of Q1 2020 after selling out during the quarter.
  • Federated Hermes sold 20 Lineage Cell Therapeutics shares in Q1 2020, an estimated $1K.
  • Federated Hermes first reported a position in Lineage Cell Therapeutics in Q4 2019 and held it in 1 quarter.
  • Federated Hermes's Lineage Cell Therapeutics position peaked at $1K in Q4 2019.
  • 97 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q1 2020.

Based on Federated Hermes's 13F filing for Q1 2020, filed 13 May 2020.